Call to Buy Nevirapine for Developing Countries

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Call to Buy Nevirapine for Developing Countries

Nature Medicine (10/99) Vol. 5, No. 10, P. 1093
Renault, Beatrice; Birmingham, Karen

The results of a joint trial between the United States and Uganda, called HIVNET012, indicate that the drug nevirapine can reduce perinatal HIV transmission by 47 percent. As a result, the Elizabeth Glaser Pediatric AIDS Foundation recently put a full-page advertisement in the New York Times asking for $12 million to help reduce the number of HIV- infected newborns. The foundation--which calculated the price based on the number of HIV-infected pregnant women in the world, the price of nevirapine, and implementation costs--will distribute the money, with preference given to areas that demonstrate they can help pregnant women with the necessary infrastructure. Already, the Glaser Foundation has committed $1 million, while the Global Strategies for HIV prevention organization and the International AIDS Society have each agreed to give $10,000.

991021
AD991782

Copyright © 1999 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.